Financial Data and Key Metrics Changes - For Q3 2023, the company reported revenue of $286.1 million, a decrease of 1.7% on an as-reported basis and 0.3% on a constant currency basis [53][56] - GAAP gross profit was $189.5 million with a margin of 66.2%, down from $202.9 million and 69.7% in the prior year [7][73] - Adjusted net income was $39.8 million with earnings per share of $0.69, while GAAP net income was $15.2 million with earnings per diluted share of $0.26 [8][73] - The company raised its guidance for adjusted gross margin to approximately 66%, up from 64.5%, and adjusted EBITDA margin to approximately 33.5%, up from 32.5% [9][75] Business Line Data and Key Metrics Changes - The core injection business grew approximately 0.5% on a constant currency basis when normalizing for non-diabetes products [53][6] - U.S. revenue totaled $153.9 million, reflecting a year-over-year constant currency decline of 2.6% [43][56] - International revenue was $132.2 million, showing a year-over-year constant currency growth of 2.4% [6][55] Market Data and Key Metrics Changes - U.S. revenues were relatively flat on a constant currency basis, while international revenues grew approximately 3.2%, driven by emerging markets [54][56] - The company anticipates a 3.6% constant currency headwind in Q4 due to the lack of contract manufacturing revenue [14][74] Company Strategy and Development Direction - The company is focused on strengthening its base business, separating from BD, and investing in growth initiatives, particularly in the insulin patch pump program [41][52] - The company is monitoring competitive threats from new drug developments, including once-weekly insulin and GLP-1s, and is exploring opportunities to leverage its manufacturing capabilities [20][85] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the execution of strategic priorities and raised financial guidance based on better-than-expected Q3 performance [10][75] - The company is cautious about the impact of contract manufacturing revenue and anticipates a sequential step down in margins due to temporary operational suspensions [57][82] Other Important Information - The company has begun the demerger process for its manufacturing facility in Suzhou, China, and is implementing an ERP solution during the temporary suspension of operations [16][23] - The company holds approximately $317 million in cash and cash equivalents and $1.64 billion in debt, resulting in a net leverage ratio of approximately 3.4x [56] Q&A Session Questions and Answers Question: What are the expectations for the China facility shutdown and margin improvement? - Management indicated that the timing for the facility shutdown is still being determined and that they will provide a multi-year outlook as they progress [32][64] Question: How does the company plan to address the impact of new drug developments like GLP-1s? - Management is closely monitoring the market and believes it is too early to determine the long-term impact of GLP-1s on their business, noting that growth is primarily in emerging markets [20][85] Question: What are the assumptions for base business growth and volume growth in the U.S. and international markets? - The company anticipates core injection business growth of 1.3% to 3.3% on a constant currency basis in Q4, driven by expectations in both the U.S. and China [62][74]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41186 | | Trading | Name of each exchange | | --- | --- | --- | | Title of each class | symbol(s) | on which r ...

Embecta Corp. (NASDAQ:EMBC) Q2 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President, Investor Relations Dev Kurdikar - Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Sam Eiber - BTIG Travis Steed - Bank of America Securities Anthony Petrone - Mizuho Securities Operator Welcome, ladies and gentlemen to the Fiscal Second Quarter 2023 Embecta Earnings Conference Call. At this ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 Or For the transition period from to Commission file number 001-41186 EMBECTA CORP. (Exact name of registrant as specified in its charter) (State or other jurisdiction of in ...

Embecta Corp. (NASDAQ:EMBC) Q1 2023 Earnings Conference Call February 14, 2023 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President, Investor Relations Dev Kurdikar - Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Marie Thibault - BTIG Travis Steed - Bank of America Operator Welcome, ladies and gentlemen to the Fiscal First Quarter 2023 Embecta Earnings Conference Call. [Operator Instructions] Please note that this ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41186 EMBECTA CORP. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission file number 001-41186 EMBECTA CORP. (Exact name of registrant as specified in its charter) Delaware 87-1583942 (State or other jurisdiction of incorporatio ...

Table of Contents Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share EMBC The Nasdaq Stock Market LLC (Nasdaq Glob Select Market) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC ...

Embecta Corp. (NASDAQ:EMBC) Q3 2022 Earnings Conference Call August 15, 2022 8:00 AM ET Company Participants Pravesh Khandelwal – Head-Investor Relations Dev Kurdikar – Chief Executive Officer Jake Elguicze – Chief Financial Officer Conference Call Participants Travis Steed – Bank of America Cecilia Furlong – Morgan Stanley Marie Thibault – BTIG Operator Please stand by. Welcome, ladies and gentlemen, to the Third Quarter Fiscal Year 2022 Earnings Conference Call for Embecta Corp. At this time all participa ...

Embecta Corp. (NASDAQ:EMBC) Q2 2022 Results Earnings Conference Call May 13, 2022 8:00 AM ET Company Participants Devdatt Kurdikar - President and Chief Executive Officer Jake Elguicze - Senior Vice President and Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Securities Cecilia Furlong - Morgan Stanley Danielle Antalffy - SVB Securities Mathew Blackman - Stifel Institutional Operator Please stand by. Welcome, ladies and gentlemen, to the second quarter of fiscal year 2022 earning ...